Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease; H.R.1796, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act; H.R.5178, Sickle Cell Disease Comprehensive Care Act.
2026 · 3rd Quarter (July 1 - Sep 30)
LEAVITT PARTNERS, LLC ON BEHALF OF SICKLE CELL DISEASE PARTNERSHIP
Filed by OGR.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 17, 2026
- Income
- $20,000.00
- Expenses
- Not reported
- Registrant
- OGR
- Filing UUID
- deecb5f7-2040-4649-b15c-c015fc296814
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.